[A19-56] Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 15.10.2019

Project no.:

Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Women whose advanced BRCA1/2-mutated high-grade epithelial ovarian cancer has responded completely or partially to first-line platinum-based chemotherapy

Result of dossier assessment:

Several hints of greater harm regarding side effects; no informative results regarding overall survival. Added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.